IPO Trending
PARSME / NSEListed

Par Drugs and Chemicals Limited

Par Drugs and Chemicals Limited, incorporated in 1999 and based in Gujarat, is engaged in the manufacturing and development of active pharmaceutical ingredients (APIs) and fine chemicals for both domestic and international markets. Its APIs are used in tablets, capsules, and other finished dosages, and it also produces various antacid molecules. The company operates two manufacturing facilities in Ankleshwar and Bhavnagar, Gujarat, and offers a portfolio of 6 fine chemicals and 12 API products sold across 17 countries. Key customers include Dabur India Ltd, Meyer Organics Pvt. Ltd, Cadila Healthcare Ltd., Cipla Ltd, and Pfizer Ltd. For fiscal 2018, international sales accounted for 86.88% of total revenue, while domestic sales contributed 13.12%. The company maintains a testing laboratory to ensure quality standards and provides drying operations to convert liquid products into powders for its clients.

₹51 - ₹51Open
Listed Price52.90
Listing Gain+3.73%
TimelineFixed Price IPO
Open03 May 2019
Close08 May 2019
Allotment13 May 2019
Listing16 May 2019

Quota Reservation Portions

Market MakerPortion: 84,000 shares
5.02%
HNIPortion: 7,78,000 shares
46.53%
RetailPortion: 7,80,000 shares
46.65%
EmployeePortion: 30,000 shares
1.79%

Minimum Application Bracket Matrix

Retail1 lots / 1 shares
₹1,02,000
HNI2 lots / 2 shares
₹2,04,000

About the Company

Par Drugs and Chemicals Limited, incorporated in 1999 and based in Gujarat, is engaged in the manufacturing and development of active pharmaceutical ingredients (APIs) and fine chemicals for both domestic and international markets. Its APIs are used in tablets, capsules, and other finished dosages, and it also produces various antacid molecules. The company operates two manufacturing facilities in Ankleshwar and Bhavnagar, Gujarat, and offers a portfolio of 6 fine chemicals and 12 API products sold across 17 countries. Key customers include Dabur India Ltd, Meyer Organics Pvt. Ltd, Cadila Healthcare Ltd., Cipla Ltd, and Pfizer Ltd. For fiscal 2018, international sales accounted for 86.88% of total revenue, while domestic sales contributed 13.12%. The company maintains a testing laboratory to ensure quality standards and provides drying operations to convert liquid products into powders for its clients.

Company Promoters

Mr. Falgun Vallabhbhai SavaniMr. Jignesh Vallabhbhai Savani